ALLO Allogene Therapeutics Inc

Price (delayed)

$2.025

Market cap

$698.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

$658.34M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 73
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 13

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
The EPS has grown by 37% YoY and by 11% from the previous quarter
The net income has increased by 31% YoY and by 9% QoQ
Allogene Therapeutics's equity has decreased by 28% YoY and by 4.7% QoQ

Key stats

What are the main financial stats of ALLO

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
1.25%
1 week
-10%
1 month
-10.4%
1 year
56.98%
YTD
47.81%
QTD
-17.01%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$190.22M
Net income
-$173.76M
Gross margin
N/A
Net margin
N/A
The net income has increased by 31% YoY and by 9% QoQ
ALLO's operating income is up by 29% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does ALLO's price correlate with its fundamentals

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
1.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 37% YoY and by 11% from the previous quarter
ALLO's price to book (P/B) is 46% more than its last 4 quarters average of 1.2 and 9% more than its 5-year quarterly average of 1.6
Allogene Therapeutics's equity has decreased by 28% YoY and by 4.7% QoQ

Efficiency

How efficient is Allogene Therapeutics business performance
The return on assets has increased by 8% year-on-year and by 2.9% since the previous quarter
ALLO's return on invested capital is up by 8% year-on-year and by 2.7% since the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
ALLO's current ratio is up by 22% from the previous quarter
ALLO's quick ratio is up by 22% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
Allogene Therapeutics's equity has decreased by 28% YoY and by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.